GenesisCare invests £20m in new technology

Paul Gearing, general manager - strategic service development Europe at GenesisCare

Cancer care provider GenesisCare has invested £20m in a new technology to include in its cancer treatment.

The Mixed Reality Viewer, developed by med-tech manufacturer Brainlab, allows clinicians and patients to visualise, interpret and interact with a patient’s medical data in 3D visualisations – as if they were objects in the real world.

This technology will enable patients to be more involved and better understand the impact of their treatment plan on their cancer.

GenesisCare purchased the technology for use within its centre for diagnostics, oncology and wellbeing in Oxford as part of their integrated neuro oncology service.

‘We want to bring cutting edge technology to the UK to treat our patients efficiently resulting in the best outcomes possible,’ said Paul Gearing, general manager – strategic service development Europe at GenesisCare. ‘Oxford is our neuro super-centre and our plan is to then connect this super-centre to the rest of our network including the connection to our new state of the art centre in London.’ 

James McArthur, general manager at GenesisCare, said: ‘We are delighted to be the first to make the Brainlab Mixed Reality Viewer available to patients in the UK. 

‘Alongside the recently launched MRIdian radiotherapy technology, this is the one of a number of exciting technologies GenesisCare is making available to patients in the UK over the next 12 months.’